secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001104659-24-035556
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx reports Q4 net loss $5.1M; ibezapolstat Phase 2b shows 96% cure rate
--------------------------------------------------------------------------

- Q4 net loss $5.1M ($0.37/shr); full year net loss $14.6M ($1.15/shr).
- Year-end cash $7.5M; subsequent ATM raised ~$4.5M.
- Ibezapolstat Phase 2b: 96% clinical cure (25/26), 100% sustained cure at 30 days.
- FDA End of Phase 2 meeting scheduled April 2024; Phase 3 plan to be discussed.
- EMA granted SME designation; additional microbiome data positive vs vancomycin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465924035556/0001104659-24-035556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465924035556/tm249120d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-035556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer